BE2023C529I2 - - Google Patents

Info

Publication number: BE2023C529I2
Authority: BE; Belgium

Application number

BE2023C529C

Other languages

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-03-08

Filing date

2023-08-01

Publication date

2025-09-05

2023-08-01 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2025-09-05 Publication of BE2023C529I2 publication Critical patent/BE2023C529I2/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Oncology (AREA)
Pulmonology (AREA)
Mycology (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Biochemistry (AREA)
Communicable Diseases (AREA)
Oil, Petroleum & Natural Gas (AREA)
Neurology (AREA)
Dermatology (AREA)
Virology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)

BE2023C529C 2005-03-08 2023-08-01 BE2023C529I2 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US65976605P	2005-03-08	2005-03-08
US72816505P	2005-10-19	2005-10-19
US75271205P	2005-12-20	2005-12-20
US76245606P	2006-01-26	2006-01-26

Publications (1)

Publication Number	Publication Date
BE2023C529I2 true BE2023C529I2 (da)	2025-09-05

Family

ID=36646098

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE2023C529C BE2023C529I2 (da)	2005-03-08	2023-08-01

Country Status (27)

Country	Link
US (5)	US9487581B2 (da)
EP (6)	EP2311491A1 (da)
JP (7)	JP2006249083A (da)
KR (2)	KR100996801B1 (da)
CN (1)	CN103861102A (da)
AR (4)	AR053026A1 (da)
AU (2)	AU2006220829C1 (da)
BE (1)	BE2023C529I2 (da)
BR (2)	BRPI0608855A2 (da)
CA (4)	CA2600608A1 (da)
CY (2)	CY1121254T1 (da)
DK (2)	DK2620450T3 (da)
ES (2)	ES2569409T3 (da)
FI (1)	FIC20230027I1 (da)
FR (1)	FR23C1029I2 (da)
HU (3)	HUE041802T2 (da)
IL (3)	IL185380A0 (da)
LT (2)	LT2620450T (da)
LU (1)	LUC00312I2 (da)
MX (2)	MX2007010970A (da)
NL (1)	NL301240I2 (da)
NZ (2)	NZ561137A (da)
PL (1)	PL2620450T3 (da)
PT (1)	PT2620450T (da)
SI (2)	SI2620450T1 (da)
TW (4)	TW200719913A (da)
WO (4)	WO2006096461A2 (da)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2949290B2 (ja)	1989-07-26	1999-09-13	京セラ株式会社	アモルファスシリコン系半導体膜の製法
AR045563A1 (es)	2003-09-10	2005-11-02	Warner Lambert Co	Anticuerpos dirigidos a m-csf
DE602005026779D1 (de) *	2004-01-09	2011-04-21	Pfizer	ANTIKÖRPER GEGEN MAdCAM
JP2006249083A (ja)	2005-03-08	2006-09-21	Pharmacia & Upjohn Co Llc	抗ｍ−ｃｓｆ抗体組成物
AU2006283560B2 (en) *	2005-08-19	2011-12-08	Centocor, Inc.	Proteolysis resistant antibody preparations
CL2007002567A1 (es) *	2006-09-08	2008-02-01	Amgen Inc	Proteinas aisladas de enlace a activina a humana.
SI2486941T1 (sl)	2006-10-02	2017-08-31	E. R. Squibb & Sons, L.L.C.	Humana protitelesa, ki vežejo CXCR4 in njihova uporaba
MX2009003635A (es) *	2006-10-06	2009-04-22	Amgen Inc	Formulaciones de anticuerpos estables.
AU2012200284B2 (en) *	2006-10-06	2014-03-06	Amgen Inc.	Stable Antibody Formulations
KR100784134B1 (ko) *	2006-10-09	2007-12-12	주식회사 대웅	상피세포성장인자를 함유하는 안정한 구내염 치료용 액상조성물
PE20080857A1 (es)	2006-10-20	2008-08-19	Amgen Inc	Formulaciones a base de polipeptidos estables
WO2008127305A2 (en) *	2006-11-01	2008-10-23	Biogen Idec Ma Inc.	Method of isolating biomacromolecules using low ph and divalent cations
EP2173163A4 (en) *	2007-07-06	2010-12-08	Glaxosmithkline Llc	ANTIBODY FORMULATIONS
UA107557C2 (xx) *	2007-07-06	2015-01-26		Композиція антитіла офатумумабу
JP2010531340A (ja) *	2007-07-10	2010-09-24	エフ．ホフマン−ラロシュアーゲー	新規処方物
WO2009114040A2 (en) *	2007-09-28	2009-09-17	Centocor Ortho Biotech Inc.	Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses
CN101939336B (zh)	2007-11-12	2014-05-14	U3制药有限公司	Axl抗体
PE20091174A1 (es) *	2007-12-27	2009-08-03	Chugai Pharmaceutical Co Ltd	Formulacion liquida con contenido de alta concentracion de anticuerpo
PT2310412T (pt) *	2008-06-20	2018-05-28	Novartis Ag	Imunoglobulinas com agregação reduzida
TWI445716B (zh) *	2008-09-12	2014-07-21	Rinat Neuroscience Corp	Ｐｃｓｋ９拮抗劑類
JP5524967B2 (ja) *	2008-09-19	2014-06-18	エフ．ホフマン−ラロシュアーゲー	新規抗体処方物
EP3329911A1 (en) *	2008-09-19	2018-06-06	Pfizer Inc	Stable liquid antibody formulation
CA2739352C (en)	2008-10-29	2021-07-13	Wyeth Llc	Methods for purification of single domain antigen binding molecules
US9393304B2 (en) *	2008-10-29	2016-07-19	Ablynx N.V.	Formulations of single domain antigen binding molecules
BRPI0921320A2 (pt) *	2008-11-28	2018-05-22	Abbott Laboratories	composições de anticorpo estáveis e métodos para estabilizar os mesmos
EP2196476A1 (en) *	2008-12-10	2010-06-16	Novartis Ag	Antibody formulation
KR20120035145A (ko)	2009-05-11	2012-04-13	우드라이 파마 게엠베하	인간화 ａｘｌ 항체
WO2011008770A2 (en) *	2009-07-14	2011-01-20	Biogen Idec Ma Inc.	Methods for inhibiting yellow color and peroxide formation in a composition
SI3133083T1 (sl) *	2009-10-01	2020-07-31	F. Hoffmann-La Roche Ag	Končna filtracija v več korakih
PL2542257T3 (pl)	2010-03-01	2018-01-31	Bayer Healthcare Llc	Zoptymalizowane przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI)
AR080698A1 (es)	2010-04-01	2012-05-02	Imclone Llc	Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
FI3722808T3 (fi)	2010-10-25	2024-12-10	Biogen Ma Inc	Menetelmiä alfa-4-integriinin aktiivisuuserojen määrittämiseksi svcam- ja/tai smadcam-pitoisuuksien erojen korrelaation avulla
TWI618543B (zh)	2010-11-05	2018-03-21	諾華公司	Ｉｌ-１７抗體用於製備治療強直性脊椎炎之藥物之用途
WO2012111762A1 (ja) *	2011-02-17	2012-08-23	協和発酵キリン株式会社	抗ｃｄ４０抗体の高濃度製剤
CN108969761A (zh)	2011-05-02	2018-12-11	米伦纽姆医药公司	抗α4β7抗体的制剂
JP2014520873A (ja) *	2011-07-18	2014-08-25	ザユニバーシティオブメルボルン	ｃ−Ｆｍｓアンタゴニストの使用
US20130064811A1 (en) *	2011-09-09	2013-03-14	International Business Machines Corporation	Methods to Enhance Cancer Treatment
ES2705538T3 (es) *	2012-01-30	2019-03-25	Arecor Ltd	Composiciones acuosas de anticuerpo estabilizadas
CN104520326A (zh) *	2012-06-21	2015-04-15	Ucb医药有限公司	药物制剂
US9592297B2 (en)	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
UA117466C2 (uk)	2012-12-13	2018-08-10	Мерк Шарп Енд Доме Корп.	СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
KR20150136061A (ko)	2013-02-01	2015-12-04	산타 마리아 바이오테라퓨틱스, 인코포레이티드	대상에 항-액티빈-a 화합물의 투여
CA3289338A1 (en) *	2013-03-12	2025-11-29	Primal Therapies, Inc.	Dental composition comprising chelator and base
BR112015023498A2 (pt) *	2013-03-15	2017-10-10	Glaxosmithkline Ip No 2 Ltd	formulação para uma proteína terapêutica
US9856316B2 (en)	2013-04-12	2018-01-02	Morphosys Ag	Antibodies targeting M-CSF
US10376582B2 (en)	2013-10-16	2019-08-13	Outlook Therapeutics, Inc.	Buffer formulations for enhanced antibody stability
JP2014062100A (ja) *	2013-11-05	2014-04-10	Glaxosmithkline Llc	抗体処方
EP2946765B1 (en)	2014-05-23	2016-08-31	Ares Trading S.A.	Liquid pharmaceutical composition
ES2572919T3 (es)	2014-05-23	2016-06-03	Ares Trading S.A.	Composición farmacéutica líquida
CN105296433B (zh) *	2014-08-01	2018-02-09	中山康方生物医药有限公司	一种ctla4抗体、其药物组合物及其用途
CN104357394B (zh) *	2014-10-24	2017-03-22	杭州阿诺生物医药科技股份有限公司	一种自体外周血淋巴细胞dc‑cik的培养方法
MX382408B (es)	2014-10-24	2025-03-13	Merck Sharp & Dohme Llc	Coagonistas de los receptores de glucagón y de glp-1.
CN105669867A (zh) *	2014-11-21	2016-06-15	上海中信国健药业股份有限公司	抗gitr/ctla-4双特异性抗体及其制备方法和用途
AR103173A1 (es) *	2014-12-22	2017-04-19	Novarits Ag	Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CA2916283C (en)	2015-01-09	2024-07-02	Pfizer Inc.	MADCAM ANTAGONIST DOSING REGIMEN
US10696735B2 (en)	2015-01-21	2020-06-30	Outlook Therapeutics, Inc.	Modulation of charge variants in a monoclonal antibody composition
SMT202300365T1 (it)	2015-01-30	2023-11-13	Momenta Pharmaceuticals Inc	Anticorpi fcrn e loro metodi di utilizzo
EP3053572A1 (en) *	2015-02-06	2016-08-10	Ares Trading S.A.	Liquid pharmaceutical composition
JP6247241B2 (ja) *	2015-02-27	2017-12-13	ノバルティスアーゲー	抗体処方
DK3283107T3 (da)	2015-04-17	2020-08-31	Bristol Myers Squibb Co	Sammensætninger omfattende en kombination af ipilimumab og nivolumab
US20180256715A1 (en) *	2015-05-13	2018-09-13	The Board Of Regents Of The University Of Texas System	Anti-ctla-4 blockade
DK3303394T3 (da)	2015-05-29	2020-07-06	Agenus Inc	Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
AR104847A1 (es) *	2015-06-17	2017-08-16	Lilly Co Eli	Formulación de anticuerpo anti-cgrp
WO2017051273A1 (en) *	2015-09-22	2017-03-30	Pfizer Inc.	Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method
CN106620691B (zh) *	2015-11-04	2020-08-21	信达生物制药(苏州)有限公司	一种重组全人源抗ctla-4单克隆抗体制剂及其应用
ES3041885T3 (en)	2016-01-08	2025-11-17	Replimune Ltd	Engineered virus
US20190241658A1 (en) *	2016-01-10	2019-08-08	Modernatx, Inc.	Therapeutic mRNAs encoding anti CTLA-4 antibodies
US11285210B2 (en)	2016-02-03	2022-03-29	Outlook Therapeutics, Inc.	Buffer formulations for enhanced antibody stability
GB201604124D0 (en) *	2016-03-10	2016-04-27	Ucb Biopharma Sprl	Pharmaceutical formulation
CN105777858B (zh) *	2016-03-22	2019-09-10	东软威特曼生物科技(南京)有限公司	多种抗体的复合稳定剂及其使用方法
US11542332B2 (en)	2016-03-26	2023-01-03	Bioatla, Inc.	Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
SG11201807474SA (en) *	2016-04-25	2018-11-29	Medimmune Llc	Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies
SG11201810509PA (en)	2016-06-20	2018-12-28	Kymab Ltd	Anti-pd-l1 antibodies
WO2018035710A1 (en)	2016-08-23	2018-03-01	Akeso Biopharma, Inc.	Anti-ctla4 antibodies
WO2018041121A1 (en)	2016-08-31	2018-03-08	Beijing Biocytogen Co., Ltd	Genetically modified non-human animal with human or chimeric ctla-4
CN107815468B (zh)	2016-08-31	2021-03-16	百奥赛图(北京)医药科技股份有限公司	人源化基因改造动物模型的制备方法及应用
CN107815467B (zh)	2016-08-31	2021-03-16	百奥赛图(北京)医药科技股份有限公司	人源化基因改造动物模型的制备方法及应用
WO2018098352A2 (en)	2016-11-22	2018-05-31	Jun Oishi	Targeting kras induced immune checkpoint expression
CN106432499A (zh) *	2016-11-24	2017-02-22	上海美迪西生物医药股份有限公司	Ctla‑4抗体fab在昆虫表达系统中的制备方法
AU2017373944B2 (en)	2016-12-07	2022-02-03	Agenus Inc.	Anti-CTLA-4 antibodies and methods of use thereof
GB201700350D0 (en)	2017-01-09	2017-02-22	Replimune Ltd	Altered virus
US11608357B2 (en)	2018-08-28	2023-03-21	Arecor Limited	Stabilized antibody protein solutions
GB201703062D0 (en)	2017-02-24	2017-04-12	Arecor Ltd	Stabilized antibody protein solutions
EP3372241A1 (en)	2017-03-06	2018-09-12	Ares Trading S.A.	Liquid pharmaceutical composition
EP3372242A1 (en)	2017-03-06	2018-09-12	Ares Trading S.A.	Liquid pharmaceutical composition
CN106913869B (zh) *	2017-03-17	2020-07-28	信达生物制药(苏州)有限公司	一种抗ctla-4单克隆抗体制剂及其应用
JOP20190260A1 (ar)	2017-05-02	2019-10-31	Merck Sharp & Dohme	صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
KR102624564B1 (ko) *	2017-05-02	2024-01-12	머크 샤프 앤드 돔 엘엘씨	항-ctla4 항체 단독의, 및 프로그램화된 사멸 수용체 1 (pd-1) 항체와 조합된 항-ctla4 항체의 안정한 제제 및 그의 사용 방법
WO2018204374A1 (en)	2017-05-02	2018-11-08	Merck Sharp & Dohme Corp.	Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
US10676516B2 (en)	2017-05-24	2020-06-09	Pandion Therapeutics, Inc.	Targeted immunotolerance
WO2019006003A1 (en) *	2017-06-27	2019-01-03	The Trustees Of Princeton University	COMPOSITIONS AND METHODS FOR IMPROVING IMMUNOTHERAPY
EA202090286A1 (ru)	2017-07-14	2020-05-12	Пфайзер, Инк.	АНТИТЕЛА К MAdCAM
MX2020001525A (es)	2017-08-24	2020-03-20	Novo Nordisk As	Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
AU2018327171B2 (en)	2017-08-31	2023-03-09	Daiichi Sankyo Company, Limited	Improved method for producing antibody-drug conjugate
ES2991988T3 (es)	2017-10-30	2024-12-05	Takeda Pharmaceuticals Co	Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
US10174092B1 (en)	2017-12-06	2019-01-08	Pandion Therapeutics, Inc.	IL-2 muteins
US10946068B2 (en)	2017-12-06	2021-03-16	Pandion Operations, Inc.	IL-2 muteins and uses thereof
JP7420720B2 (ja)	2017-12-13	2024-01-23	モメンタファーマシューティカルズインコーポレイテッド	ＦｃＲｎ抗体およびその使用方法
US11324774B2 (en)	2018-01-05	2022-05-10	Augusta University Research Institute, Inc.	Compositions of oral alkaline salts and metabolic acid inducers and uses thereof
IL277095B2 (en) *	2018-03-07	2025-10-01	Pfizer	Preparations containing anti-PD-1 antibody
IL280280B2 (en) *	2018-07-20	2024-11-01	Momenta Pharmaceuticals Inc	Compositions of fcrn antibodies and methods of use thereof
CR20210076A (es)	2018-07-20	2021-09-02	Momenta Pharmaceuticals Inc	Composiciones de anticuerpo fcrn
WO2020033467A1 (en) *	2018-08-07	2020-02-13	The Brigham And Women's Hospital, Inc.	Methods compositions relating to inhibiting cardiovascular calcification via annexin a1
WO2020046820A1 (en) *	2018-08-26	2020-03-05	Hair Plus Health Llc	Methods and compositions to increase hair growth and/or prevent hair loss
NZ775959A (en) *	2018-10-31	2022-08-26	Bioatla Inc	Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
BR112021008873A8 (pt)	2018-11-07	2023-04-11	Merck Sharp & Dohme	Formulação
RU2754760C2 (ru)	2019-04-02	2021-09-07	Закрытое Акционерное Общество "Биокад"	Водная фармацевтическая композиция анти-il17a антитела и ее применение
CN114679909A (zh) *	2019-05-20	2022-06-28	潘迪恩运营公司	MAdCAM靶向的免疫耐受
MX2021014804A (es)	2019-06-04	2022-01-18	Jiangsu Hengrui Medicine Co	Anticuerpo capaz de unirse a la linfopoyetina estromal timica y el uso del mismo.
TW202539734A (zh)	2019-09-20	2025-10-16	瑞士商諾華公司	使用白細胞介素-17（il-17）拮抗劑治療自體免疫性疾病之方法
AU2020356303A1 (en) *	2019-09-23	2022-04-14	Merck Sharp & Dohme Llc	Methods and compositions comprising an anti-CTLA4 monoclonal antibody with reduced host cell proteins and increased polysorbate-80 stability
MX2022005836A (es) *	2019-11-13	2022-06-09	Pfizer	Formulacion estable de anticuerpos acuosos.
US20230203164A1 (en) *	2019-12-25	2023-06-29	Bio-Thera Solutions, Ltd.	Anti-ctla-4 monoclonal antibody, preparation method therefor, and application thereof
IL294521A (en)	2020-02-18	2022-09-01	Novo Nordisk As	glp-1 compounds and their uses
US11981715B2 (en)	2020-02-21	2024-05-14	Pandion Operations, Inc.	Tissue targeted immunotolerance with a CD39 effector
CN115605185A (zh) *	2020-05-19	2023-01-13	豪夫迈·罗氏有限公司（Ch）	螯合剂用于防止胃肠外蛋白质溶液中形成可见颗粒的用途
AU2021316119A1 (en) *	2020-07-31	2023-03-02	Alamab Therapeutics, Inc.	Anti-connexin antibody formulations
AR123340A1 (es) *	2020-08-26	2022-11-23	Janssen Biotech Inc	FORMULACIONES ESTABLES QUE COMPRENDEN UN ANTICUERPO BIESPECÍFICO PARA EGFR / c-MET
EP4225940A4 (en) *	2020-10-06	2025-01-01	Materials and Machines Corporation of America	METHOD FOR DETECTING RNA OR DNA FROM BIOLOGICAL SAMPLES
WO2022106976A1 (en)	2020-11-18	2022-05-27	Pfizer Inc.	Stable pharmaceutical formulations of soluble fgfr3 decoys
KR20230116857A (ko) *	2020-12-03	2023-08-04	지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드	항 tslp 항체의 약학 조성물 및 이의 용도
CN112569183B (zh) *	2020-12-11	2022-12-09	上海赛金生物医药有限公司	一种抗ctla-4抗体及融合蛋白的制剂
TW202308689A (zh) *	2021-04-21	2023-03-01	美商健生生物科技公司	高濃度的雙特異性抗體調配物
KR20250099736A (ko) *	2022-11-04	2025-07-02	아스트라제네카 아베	항-ctla 항체 조성물 및 관련 방법
EP4623004A1 (en)	2022-11-22	2025-10-01	Takeda Pharmaceutical Company Limited	Dosage regimen of madcam-1 antibody for treatment of non-alcoholic steatohepatitis
JP2026500069A (ja) *	2023-03-09	2026-01-06	メルク・シャープ・アンド・ドーム・エルエルシー	ＡｃｔＲＩＩＡタンパク質変異体を含む製剤
WO2024262576A1 (ja)	2023-06-20	2024-12-26	国立大学法人東京大学	免疫刺激型ヘルペスウイルス
CN117554633A (zh) *	2023-11-14	2024-02-13	四川沃文特生物技术有限公司	一种用于测定prl催乳素的检测试剂盒
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en)	1982-11-18	1985-04-09	Chiron Corporation	Adenovirus promoter system
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4740461A (en)	1983-12-27	1988-04-26	Genetics Institute, Inc.	Vectors and methods for transformation of eucaryotic cells
US4597966A (en) *	1985-01-09	1986-07-01	Ortho Diagnostic Systems, Inc.	Histidine stabilized immunoglobulin and method of preparation
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
EP0216846B2 (en)	1985-04-01	1995-04-26	Celltech Limited	Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4968615A (en)	1985-12-18	1990-11-06	Ciba-Geigy Corporation	Deoxyribonucleic acid segment from a virus
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US4959455A (en)	1986-07-14	1990-09-25	Genetics Institute, Inc.	Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en)	1986-11-14	1990-03-27	Genetics Institute, Inc.	Eucaryotic expression system
RU1438240C (ru)	1987-04-22	1996-03-20	Институт биоорганической химии им.М.М.Шемякина и Ю.А.Овчинникова РАН	РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК РТNF 22, СОДЕРЖАЩАЯ ПОЛУСИНТЕТИЧЕСКИЙ ГЕН ФАКТОРА НЕКРОЗА ОПУХОЛИ ЧЕЛОВЕКА - ПРОМЕЖУТОЧНАЯ ПЛАЗМИДА ДЛЯ КОНСТРУИРОВАНИЯ РЕКОМБИНАНТНОЙ ПЛАЗМИДНОЙ ДНК pTNF 31, КОДИРУЮЩАЯ ПОЛИПЕПТИД СО СВОЙСТВАМИ ФАКТОРА НЕКРОЗА ОПУХОЛИ ЧЕЛОВЕКА, И ШТАММ БАКТЕРИЙ ESCHERICHIA COLI - ПРОДУЦЕНТ ПОЛИПЕПТИДА СО СВОЙСТВАМИ ФАКТОРА НЕКРОЗА ОПУХОЛИ ЧЕЛОВЕКА
US5750172A (en)	1987-06-23	1998-05-12	Pharming B.V.	Transgenic non human mammal milk
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5175384A (en)	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5633076A (en)	1989-12-01	1997-05-27	Pharming Bv	Method of producing a transgenic bovine or transgenic bovine embryo
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
DK0463151T3 (da)	1990-01-12	1996-07-01	Cell Genesys Inc	Frembringelse af xenogene antistoffer
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6673986B1 (en)	1990-01-12	2004-01-06	Abgenix, Inc.	Generation of xenogeneic antibodies
US5217954A (en) *	1990-04-04	1993-06-08	Scios Nova Inc.	Formulations for stabilizing fibroblast growth factor
US5151510A (en)	1990-04-20	1992-09-29	Applied Biosystems, Inc.	Method of synethesizing sulfurized oligonucleotide analogs
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
JP2938569B2 (ja)	1990-08-29	1999-08-23	ジェンファームインターナショナル，インコーポレイティド	異種免疫グロブリンを作る方法及びトランスジェニックマウス
CA2090473A1 (en)	1990-08-29	1992-03-01	Robert M. Kay	Homologous recombinatin in mammalian cells
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5851795A (en)	1991-06-27	1998-12-22	Bristol-Myers Squibb Company	Soluble CTLA4 molecules and uses thereof
WO1993004169A1 (en)	1991-08-20	1993-03-04	Genpharm International, Inc.	Gene targeting in animal cells using isogenic dna constructs
JPH0595794A (ja) *	1991-10-04	1993-04-20	Otsuka Pharmaceut Co Ltd	ヒトｍ−ｃｓｆ抗体及びヒトｍ−ｃｓｆの測定法
GB9122820D0 (en) *	1991-10-28	1991-12-11	Wellcome Found	Stabilised antibodies
JP2942412B2 (ja) *	1991-12-26	1999-08-30	鐘紡株式会社	化粧料
EP0652950B1 (en)	1992-07-24	2007-12-19	Amgen Fremont Inc.	Generation of xenogeneic antibodies
WO1994019020A1 (en) *	1993-02-23	1994-09-01	Genentech, Inc.	Excipient stabilization of polypeptides treated with organic solvents
ES2146648T3 (es)	1993-03-09	2000-08-16	Genzyme Corp	Procedimiento de aislamiento de proteinas de la leche.
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
US5643763A (en)	1994-11-04	1997-07-01	Genpharm International, Inc.	Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US7803904B2 (en) *	1995-09-01	2010-09-28	Millennium Pharmaceuticals, Inc.	Mucosal vascular addressing and uses thereof
US6130364A (en)	1995-03-29	2000-10-10	Abgenix, Inc.	Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en)	1995-03-29	2000-07-18	Abgenix, Inc.	Production of antibodies using Cre-mediated site-specific recombination
CA2218489A1 (en)	1995-04-21	1996-10-24	Aya Jakobovits	Generation of large genomic dna deletions
DE69637481T2 (de)	1995-04-27	2009-04-09	Amgen Fremont Inc.	Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en)	1995-04-28	1996-11-18	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6267958B1 (en) *	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
US20020081294A1 (en)	1996-01-23	2002-06-27	Genentech, Inc.	Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US5714352A (en)	1996-03-20	1998-02-03	Xenotech Incorporated	Directed switch-mediated DNA recombination
US5994619A (en)	1996-04-01	1999-11-30	University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus	Production of chimeric bovine or porcine animals using cultured inner cell mass cells
GB9610992D0 (en)	1996-05-24	1996-07-31	Glaxo Group Ltd	Concentrated antibody preparation
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
CA2273194C (en)	1996-12-03	2011-02-01	Abgenix, Inc.	Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
WO1998056418A1 (en) *	1997-06-13	1998-12-17	Genentech, Inc.	Stabilized antibody formulation
US6171586B1 (en)	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
KR20010034554A (ko)	1998-03-03	2001-04-25	레이몬드, 엠. 위티	치료제로서의 ｃｄ147 결합 분자
US20020029391A1 (en)	1998-04-15	2002-03-07	Claude Geoffrey Davis	Epitope-driven human antibody production and gene expression profiling
AU770555B2 (en)	1998-08-17	2004-02-26	Abgenix, Inc.	Generation of modified molecules with increased serum half-lives
US6682736B1 (en)	1998-12-23	2004-01-27	Abgenix, Inc.	Human monoclonal antibodies to CTLA-4
CA2356215C (en)	1998-12-23	2015-11-24	Pfizer Inc.	Human monoclonal antibodies to ctla-4
US7605238B2 (en)	1999-08-24	2009-10-20	Medarex, Inc.	Human CTLA-4 antibodies and their uses
ATE354655T1 (de) *	1999-08-24	2007-03-15	Medarex Inc	Humane antikörper gegen ctla-4 und deren verwendungen
US6517529B1 (en)	1999-11-24	2003-02-11	Radius International Limited Partnership	Hemodialysis catheter
EP1336410A4 (en)	2000-08-04	2005-10-12	Chugai Pharmaceutical Co Ltd	PROTEIN INJECTION PREPARATIONS
EP1314437B1 (en) *	2000-08-11	2014-06-25	Chugai Seiyaku Kabushiki Kaisha	Stabilized antibody-containing preparations
IL149701A0 (en)	2001-05-23	2002-11-10	Pfizer Prod Inc	Use of anti-ctla-4 antibodies
CA2454587C (en) *	2001-07-25	2012-11-13	Protein Design Labs, Inc.	Stable lyophilized pharmaceutical formulation of igg antibodies
NZ532896A (en) *	2001-11-08	2007-08-31	Pdl Biopharma Inc	Stable liquid pharmaceutical formulation of IGG antibodies including daclizumab and fontolizumab
MXPA04004646A (es) *	2001-11-15	2004-08-12	Koninkl Philips Electronics Nv	Metodo de grabacion de portador de grabacion optico y aparato de grabacion.
US7452539B2 (en)	2001-12-19	2008-11-18	Genentech, Inc.	Stabilizing polypeptides which have been exposed to urea
PL213311B1 (pl)	2002-02-14	2013-02-28	Chugai Pharmaceutical Co Ltd	Preparat roztworu zawierajacego przeciwcialo
US7132100B2 (en) *	2002-06-14	2006-11-07	Medimmune, Inc.	Stabilized liquid anti-RSV antibody formulations
EP1551875A4 (en) *	2002-06-21	2006-06-28	Biogen Idec Inc	TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
JP2006502116A (ja)	2002-07-12	2006-01-19	メダレックス，インク．	タンパク質の酸化分解を防ぐ方法及び組成物
AU2003291002A1 (en) *	2002-11-15	2004-06-15	Chiron Corporation	Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
AU2003293543A1 (en) *	2002-12-13	2004-07-09	Abgenix, Inc.	System and method for stabilizing antibodies with histidine
WO2004071439A2 (en) *	2003-02-10	2004-08-26	Elan Pharmaceuticals, Inc.	Immunoglobulin formulation and method of preparation thereof
PL1610820T5 (pl) *	2003-04-04	2014-01-31	Genentech Inc	Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
AR045563A1 (es) *	2003-09-10	2005-11-02	Warner Lambert Co	Anticuerpos dirigidos a m-csf
DE602005026779D1 (de) *	2004-01-09	2011-04-21	Pfizer	ANTIKÖRPER GEGEN MAdCAM
US20060008415A1 (en) *	2004-06-25	2006-01-12	Protein Design Labs, Inc.	Stable liquid and lyophilized formulation of proteins
JO3000B1 (ar) *	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
AU2006208226A1 (en) *	2005-01-24	2006-08-03	Amgen Inc.	Humanized anti-amyloid antibody
AR054428A1 (es) *	2005-03-08	2007-06-27	Pharmacia & Upjohn Co Llc	Composiciones de anticuerpos anti factor estimulante de colonia de macrofagos (anti-m-csf) que tienen menores niveles de endotoxina
JP2006249083A (ja)	2005-03-08	2006-09-21	Pharmacia & Upjohn Co Llc	抗ｍ−ｃｓｆ抗体組成物
CN101227923A (zh) *	2005-07-08	2008-07-23	辉瑞有限公司	抗-MAdCAM抗体在治疗腹部疾病及热带口炎性腹泻中的用途

2006
- 2006-03-02 JP JP2006056813A patent/JP2006249083A/ja active Pending
- 2006-03-02 JP JP2006056870A patent/JP2006249085A/ja active Pending
- 2006-03-02 AR ARP060100793A patent/AR053026A1/es not_active Application Discontinuation
- 2006-03-02 US US11/817,894 patent/US9487581B2/en active Active
- 2006-03-02 US US11/817,898 patent/US20080248047A1/en not_active Abandoned
- 2006-03-02 MX MX2007010970A patent/MX2007010970A/es unknown
- 2006-03-02 KR KR1020077020428A patent/KR100996801B1/ko not_active Expired - Fee Related
- 2006-03-02 NZ NZ561137A patent/NZ561137A/en unknown
- 2006-03-02 TW TW095107035A patent/TW200719913A/zh unknown
- 2006-03-02 CA CA002600608A patent/CA2600608A1/en not_active Abandoned
- 2006-03-02 TW TW095107087A patent/TW200642694A/zh unknown
- 2006-03-02 EP EP10185318A patent/EP2311491A1/en not_active Withdrawn
- 2006-03-02 CA CA2600434A patent/CA2600434C/en active Active
- 2006-03-02 HU HUE13155091A patent/HUE041802T2/hu unknown
- 2006-03-02 DK DK13155091.5T patent/DK2620450T3/da active
- 2006-03-02 WO PCT/US2006/007461 patent/WO2006096461A2/en not_active Ceased
- 2006-03-02 CA CA002600588A patent/CA2600588A1/en not_active Abandoned
- 2006-03-02 AR AR20060100796A patent/AR054233A1/es not_active Application Discontinuation
- 2006-03-02 JP JP2006056818A patent/JP2006249084A/ja active Pending
- 2006-03-02 NZ NZ560844A patent/NZ560844A/en unknown
- 2006-03-02 WO PCT/US2006/007554 patent/WO2006096490A2/en not_active Ceased
- 2006-03-02 WO PCT/US2006/007555 patent/WO2006096491A2/en not_active Ceased
- 2006-03-02 BR BRPI0608855-4A patent/BRPI0608855A2/pt not_active IP Right Cessation
- 2006-03-02 TW TW095107021A patent/TWI365747B/zh active
- 2006-03-02 AU AU2006220829A patent/AU2006220829C1/en active Active
- 2006-03-02 US US11/817,993 patent/US20090110681A1/en not_active Abandoned
- 2006-03-02 ES ES06736812.6T patent/ES2569409T3/es active Active
- 2006-03-02 WO PCT/US2006/007551 patent/WO2006096488A2/en not_active Ceased
- 2006-03-02 HU HUE06736812A patent/HUE028410T2/en unknown
- 2006-03-02 BR BRPI0608815-5A patent/BRPI0608815B1/pt active IP Right Grant
- 2006-03-02 MX MX2007010971A patent/MX2007010971A/es active IP Right Grant
- 2006-03-02 EP EP06736811A patent/EP1871806A2/en not_active Withdrawn
- 2006-03-02 SI SI200632306T patent/SI2620450T1/sl unknown
- 2006-03-02 AR ARP060100795A patent/AR062247A1/es not_active Application Discontinuation
- 2006-03-02 US US11/815,259 patent/US20090238820A1/en not_active Abandoned
- 2006-03-02 PT PT13155091T patent/PT2620450T/pt unknown
- 2006-03-02 AR ARP060100794A patent/AR053553A1/es not_active Application Discontinuation
- 2006-03-02 EP EP06736812.6A patent/EP1865986B1/en active Active
- 2006-03-02 EP EP06748276A patent/EP1868646A2/en not_active Withdrawn
- 2006-03-02 AU AU2006220828A patent/AU2006220828A1/en not_active Abandoned
- 2006-03-02 PL PL13155091T patent/PL2620450T3/pl unknown
- 2006-03-02 SI SI200632037A patent/SI1865986T1/sl unknown
- 2006-03-02 ES ES13155091T patent/ES2707284T3/es active Active
- 2006-03-02 KR KR1020077020433A patent/KR100989280B1/ko active Active
- 2006-03-02 CA CA002600836A patent/CA2600836A1/en not_active Abandoned
- 2006-03-02 DK DK06736812.6T patent/DK1865986T3/da active
- 2006-03-02 CN CN201410109866.6A patent/CN103861102A/zh active Pending
- 2006-03-02 EP EP06736810A patent/EP1858552A2/en not_active Withdrawn
- 2006-03-02 EP EP13155091.5A patent/EP2620450B1/en active Active
- 2006-03-02 LT LTEP13155091.5T patent/LT2620450T/lt unknown
- 2006-03-02 JP JP2006056701A patent/JP5670004B2/ja active Active
- 2006-03-03 TW TW095107092A patent/TW200709817A/zh unknown
2007
- 2007-08-20 IL IL185380A patent/IL185380A0/en unknown
- 2007-08-23 IL IL185483A patent/IL185483A/en active IP Right Grant
2010
- 2010-09-10 US US12/879,916 patent/US20110027262A1/en not_active Abandoned
2012
- 2012-05-21 JP JP2012115478A patent/JP2012167120A/ja active Pending
- 2012-10-31 JP JP2012240979A patent/JP2013032387A/ja not_active Withdrawn
2013
- 2013-03-21 IL IL225435A patent/IL225435A0/en unknown
2015
- 2015-03-04 JP JP2015042425A patent/JP6212509B2/ja active Active
2019
- 2019-01-11 CY CY20191100026T patent/CY1121254T1/el unknown
2023
- 2023-07-28 FR FR23C1029C patent/FR23C1029I2/fr active Active
- 2023-07-28 NL NL301240C patent/NL301240I2/nl unknown
- 2023-08-01 LU LU00312C patent/LUC00312I2/en unknown
- 2023-08-01 BE BE2023C529C patent/BE2023C529I2/fr unknown
- 2023-08-02 FI FIC20230027C patent/FIC20230027I1/fi unknown
- 2023-08-09 CY CY2023018C patent/CY2023018I2/el unknown
- 2023-08-09 LT LTPA2023522C patent/LTC2620450I2/lt unknown
- 2023-08-17 HU HUS2300026C patent/HUS2300026I1/hu unknown

Also Published As

Publication number	Publication date
EP1865986A2 (en)	2007-12-19
CY2023018I1 (el)	2023-11-15
LT2620450T (lt)	2019-02-11
US20080248047A1 (en)	2008-10-09
CA2600434A1 (en)	2006-09-14
JP2006249085A (ja)	2006-09-21
ES2707284T3 (es)	2019-04-03
CY2023018I2 (el)	2024-02-16
EP1868646A2 (en)	2007-12-26
NZ561137A (en)	2011-09-30
HUE028410T2 (en)	2016-12-28
DK1865986T3 (da)	2016-04-11
TW200700081A (en)	2007-01-01
MX2007010970A (es)	2007-09-19
WO2006096491A9 (en)	2008-05-29
JP2012167120A (ja)	2012-09-06
US20110027262A1 (en)	2011-02-03
KR100989280B1 (ko)	2010-10-20
WO2006096490A2 (en)	2006-09-14
NZ560844A (en)	2008-08-29
WO2006096461A2 (en)	2006-09-14
TW200642694A (en)	2006-12-16
AR062247A1 (es)	2008-10-29
CN103861102A (zh)	2014-06-18
HK1125297A1 (en)	2009-08-07
SI1865986T1 (sl)	2016-05-31
JP6212509B2 (ja)	2017-10-11
AU2006220829B2 (en)	2011-10-13
KR100996801B1 (ko)	2010-11-25
PL2620450T3 (pl)	2019-05-31
DK2620450T3 (da)	2019-02-04
BRPI0608815A8 (pt)	2017-03-21
US9487581B2 (en)	2016-11-08
TWI365747B (en)	2012-06-11
FIC20230027I1 (fi)	2023-08-02
EP2620450B1 (en)	2018-11-07
CA2600588A1 (en)	2006-09-14
LUC00312I2 (da)	2025-02-03
CY1121254T1 (el)	2020-05-29
AU2006220828A1 (en)	2006-09-14
JP2006249084A (ja)	2006-09-21
AR053026A1 (es)	2007-04-18
ES2569409T3 (es)	2016-05-10
TW200709817A (en)	2007-03-16
EP1858552A2 (en)	2007-11-28
FR23C1029I1 (fr)	2023-10-06
AU2006220829A1 (en)	2006-09-14
HUS2300026I1 (hu)	2023-09-28
HUE041802T2 (hu)	2019-05-28
US20090130119A1 (en)	2009-05-21
WO2006096488A3 (en)	2006-11-30
IL225435A0 (en)	2013-06-27
WO2006096488A2 (en)	2006-09-14
CA2600434C (en)	2017-09-19
AR054233A1 (es)	2007-06-13
AR053553A1 (es)	2007-05-09
EP2311491A1 (en)	2011-04-20
WO2006096461A3 (en)	2006-12-21
US20090238820A1 (en)	2009-09-24
BRPI0608855A2 (pt)	2010-02-02
JP5670004B2 (ja)	2015-02-18
MX2007010971A (es)	2007-09-19
JP2006249081A (ja)	2006-09-21
WO2006096491A3 (en)	2007-03-29
BRPI0608815A2 (pt)	2010-01-26
JP2013032387A (ja)	2013-02-14
EP2620450A3 (en)	2014-01-08
NL301240I2 (nl)	2025-07-31
KR20070100848A (ko)	2007-10-11
WO2006096490A3 (en)	2006-12-28
WO2006096490A8 (en)	2007-02-01
JP2006249083A (ja)	2006-09-21
CA2600836A1 (en)	2006-09-14
IL185483A0 (en)	2008-01-06
TW200719913A (en)	2007-06-01
CA2600608A1 (en)	2006-09-14
SI2620450T1 (sl)	2019-01-31
BRPI0608815B1 (pt)	2021-10-13
JP2015110656A (ja)	2015-06-18
IL185380A0 (en)	2008-02-09
PT2620450T (pt)	2018-12-17
EP1865986B1 (en)	2016-02-17
US20090110681A1 (en)	2009-04-30
WO2006096491A2 (en)	2006-09-14
KR20070100922A (ko)	2007-10-12
IL185483A (en)	2013-04-30
AU2006220829C1 (en)	2025-01-02
FR23C1029I2 (fr)	2024-06-14
LTPA2023522I1 (da)	2023-09-11
EP2620450A2 (en)	2013-07-31
EP1871806A2 (en)	2008-01-02
LTC2620450I2 (da)	2024-11-11

Publication	Publication Date	Title
LUC00312I2 (da)	2025-02-03
BE2021C557I2 (da)	2026-01-14
BE2021C524I2 (da)	2025-12-10
BE2021C519I2 (da)	2025-12-10
BE2020C531I2 (da)	2025-09-05
BE2020C511I2 (da)	2025-09-05
BE2020C508I2 (da)	2025-12-10
BE2020C004I2 (da)	2026-01-06
BE2019C521I2 (da)	2025-12-10
BE2019C503I2 (da)	2025-12-10
BE2018C037I2 (da)	2025-12-10
BE2018C035I2 (da)	2025-09-05
BE2018C016I2 (da)	2025-09-05
BE2017C028I2 (da)	2025-09-10
BE2018C028I2 (da)	2025-09-05
BE2019C533I2 (da)	2025-12-10
BE2015C074I2 (da)	2025-12-10
BE2014C012I2 (da)	2026-01-14
BE2014C057I2 (da)	2025-12-10
BE2013C074I2 (da)	2025-09-17
BE2013C014I2 (da)	2025-12-10
BE2012C042I2 (da)	2021-07-19
BE2012C028I2 (da)	2026-01-14
BRPI0601358B8 (pt)	2023-02-23	Aplicador de clipe cirúrgico
BRPI0601402B8 (pt)	2023-02-23	Aplicador de grampos cirúrgicos